40358-04-1

Usage

Safety Profile

Residue left from distillationdecomposes vigorously at 147°C. When heated todecomposition it emits toxic fumes of Clí, SOx, and NOx.

Upstream product

• 16629-19-9 thiophene-2-sulfonyl chloride 
• 7697-37-2 nitric acid 

Downstream Products

• 822-84-4 3-nitrothiophene 
• 36035-08-2 4-Nitro-thiophene-2-sulfonic acid phenylamide 
• 1361220-80-5 2-(4-(4-((4-nitro-2-thiophenyl)-sulfonyl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 

Relevant academic research and scientific papers

Pyrimidine derivatives, and preparation method and use thereof

Pyrimidine derivatives disclosed in the invention respectively contain an aromatic five-membered heterocycle, a lone electron pair on a hetero atom S, O or N and an unsaturated five-membered ring form a conjugated system, and the lone electron pair effect of above hetero atoms has an inhibition effect on vascular endothelial growth factor (VEGF) receptors VEGFR-1, VEGFR-2 and VEGFR-3, so the pyrimidine derivatives are very good kinase inhibitors. The pyrimidine derivatives have stronger VEGFR-1, VEGFR-2 and VEGFR-3 inhibition activity than pazopanib in the prior art, and can be used treat VEGF signal pathway inhibition diseases, such as lung cancer, kidney cell cancer and other solid tumors.

SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES

The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

Macrocyclic pyrimidines, their production and use as pharmaceutical agents

Macrocyclic pyrimidine derivatives of general formula I in which R1 to R5, X, Y, A, B, m and n have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinase, their processes for production as well as their use as medications for treating various diseases are described.